Solid tumor biotech’s polymer nanoparticle-drug conjugate clears early-stage hurdle, sparking PhII plans
07 Dec 2023
Phase 1Clinical ResultPhase 2ADCPROTACs
Dantari’s drug conjugate asset has produced positive data as both a monotherapy and in combination with a PARP inhibitor in an early-stage breast cancer trial, paving the way for a Phase II test.
The biotech’s Phase I dose escalation trial studied DAN-222 as a single agent and in combination with GSK’s Zejula in 30 metastatic HER2-negative breast cancer patients with a median of six prior lines of therapy. Results from the trial come one year after Dantari raised $47 million in a Series A round.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.